Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from mouse bone marrow stem cells, fetal cord blood and adult bone marrow stem cells. Phase I of this project includes testing existing mouse antibodies against Influenza for their ability to neutralize pathogenic strains of Influenza and adapting this technology to generate human antibodies against Influenza in a mouse model using human adult stem cells. Phase II of the project will involve optimizing large-scale production and testing of human anti-influenza antibodies.

Public Health Relevance

This project seeks to optimize a novel method to rapidly generate human therapeutic antibodies against the Influenza virus in a mouse model using human adult stem cell lines. Once this method has been validated for Influenza, the long-term goal to benefit public health will be to use this system to generate antibodies for clinical applications in a variety of global health issues including, but not limited to, HIV-1, tuberculosis and malaria. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI078563-01
Application #
7480790
Study Section
Special Emphasis Panel (ZRG1-IDM-Q (10))
Program Officer
Krafft, Amy
Project Start
2008-08-15
Project End
2010-07-31
Budget Start
2008-08-15
Budget End
2010-07-31
Support Year
1
Fiscal Year
2008
Total Cost
$180,667
Indirect Cost
Name
Taiga Biotechnologies, Inc.
Department
Type
DUNS #
783743938
City
Aurora
State
CO
Country
United States
Zip Code
80045